KEAP1 and Parkinson disease: Multiple studies have been conducted in rodent or transformed (e.g. neuroblastoma) human cell line models culminating in NRF2 being touted as a ‘novel therapeutic target’ for PD intervention [18] due to the ability to pharmacologically inhibit the KEAP1 - NRF2 interaction (for example, by treatment with L-Sulforaphane [L-SUL, reference 19]) and thereby concomitantly inhibit proteasomal degradation of NRF2, and increase NRF2 target gene expression.